Doorgaan naar hoofdcontent

Human medicines European public assessment report (EPAR): Gavreto, pralsetinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 18/11/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Gavreto, pralsetinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 18/11/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Gavreto, pralsetinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 18/11/2021, Revision: 6, Status: Authorised

Wil je het laatste nieuws in jouw mailbox? Meld je dan aan voor de nieuwsbrief